{
    "ticker": "TSLZ",
    "name": "Telesis Bio, Inc.",
    "description": "Telesis Bio, Inc. is a biotechnology company that specializes in the development of innovative DNA synthesis technologies for a range of applications in synthetic biology and molecular biology. Founded in 2018, the company has quickly established itself as a leader in the field of DNA synthesis, providing cutting-edge solutions for researchers and developers focused on genetic engineering, drug discovery, and agricultural biotechnology. Telesis Bio's flagship product, the BioXp\u2122 system, allows users to automate the synthesis of DNA constructs from scratch, significantly speeding up the process of creating genetic materials. This technology is particularly valuable in synthetic biology, where rapid prototyping of genetic constructs is essential for innovation and research. Telesis Bio is committed to advancing the field of synthetic biology through its proprietary technologies, enabling scientists to explore new avenues in genetic research and development. The company's mission is to empower the scientific community with tools that enhance productivity and creativity, thereby facilitating breakthroughs in medicine, agriculture, and environmental sustainability.",
    "industry": [
        "Biotechnology",
        "Synthetic Biology"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.telesisbio.com",
    "ceo": "Dan A. W. McCarthy",
    "social_media": {
        "twitter": "https://twitter.com/TelesisBio",
        "linkedin": "https://www.linkedin.com/company/telesis-bio"
    },
    "investor_relations": "https://investors.telesisbio.com",
    "key_executives": [
        {
            "name": "Dan A. W. McCarthy",
            "position": "CEO"
        },
        {
            "name": "Michael K. B. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "DNA Synthesis",
            "products": [
                "BioXp\u2122 System",
                "DNA Constructs"
            ]
        }
    ],
    "seo": {
        "meta_title": "Telesis Bio, Inc. | Innovating DNA Synthesis for Synthetic Biology",
        "meta_description": "Explore Telesis Bio, Inc., a leader in DNA synthesis technology. Discover innovative solutions for synthetic biology and molecular research.",
        "keywords": [
            "Telesis Bio",
            "DNA Synthesis",
            "Synthetic Biology",
            "Biotechnology",
            "BioXp System"
        ]
    },
    "faq": [
        {
            "question": "What does Telesis Bio specialize in?",
            "answer": "Telesis Bio specializes in innovative DNA synthesis technologies for synthetic biology and molecular biology applications."
        },
        {
            "question": "Who is the CEO of Telesis Bio?",
            "answer": "Dan A. W. McCarthy is the CEO of Telesis Bio, Inc."
        },
        {
            "question": "Where is Telesis Bio headquartered?",
            "answer": "Telesis Bio is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is the BioXp\u2122 system?",
            "answer": "The BioXp\u2122 system is Telesis Bio's flagship product that automates the synthesis of DNA constructs, speeding up genetic engineering processes."
        },
        {
            "question": "When was Telesis Bio founded?",
            "answer": "Telesis Bio was founded in 2018."
        }
    ],
    "competitors": [
        "ILMN",
        "SGEN",
        "ADPT",
        "CRSP"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "REGN",
        "GILD"
    ]
}